LEADER
2016
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
In 9,340 patients with type 2 diabetes at high cardiovascular risk, liraglutide reduced major adverse cardiovascular events compared with placebo.
Result
Efficacy: CV death, MI or strokeHR 0.87
Below 1 favours liraglutide, above 1 favours placebo.
- Absolute difference
- 1.9 points
The absolute difference is derived from the event rates.
Also reported: CV and all-cause mortality reduced.
- Subtopic
- GLP-1 RA
- Design
- Double-blind RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2021 PreventionESC 2023 DiabetesACC/AHA 2023 CCDACC/AHA 2019 Primary PreventionACC/AHA 2024 PADACC/AHA 2026 CKM
- Source
- Marso SP, et al. N Engl J Med. 2016;375(4):311-322.doi 10.1056/NEJMoa1603827
Discussion & critique
Established the cardiovascular benefit of GLP-1 receptor agonists: roughly a 14 % MACE reduction is now regarded as a class effect.